Single-use Technology: Balancing the Risks and Rewards - Developing a quality agreement template for single-use systems. - BioPharm International

ADVERTISEMENT

Single-use Technology: Balancing the Risks and Rewards
Developing a quality agreement template for single-use systems.


BioPharm International Supplements
Volume 24, Issue 9, pp. s19-s21

WHY IS A QUALITY AGREEMENT TEMPLATE NEEDED?

One of the major challenges with quality agreements that users and suppliers have experienced is that no two companies request the same information, resulting in many hours spent filling out and modifying each company's unique forms. Singleuse system suppliers are considered more responsible for the user's processes than stainless steel component or system suppliers because singleuse components could conceivably vary from lot to lot, with users being highly dependent on the quality and delivery (and repeat quality) of such systems. Consequently, users are requesting to be kept more informed of supplier process changes beyond what has been previously acceptable practice. Singleuse equipment suppliers and users must find ways to ensure suitable change notification on custom-assembled systems for users, while enabling sufficient flexibility of suppliers for updating standard products and processes. Based on a BPSA informal survey of singleuse supplier QA managers, the BPSA estimates that 60–70% of the work undertaken to establish agreements between supplier and user is redundant and does not serve any added value.

Adoption of singleuse technologies for biopharmaceutical manufacturing is growing every day, and many user and supplier companies have expressed the need for an easier way to execute quality agreements in a more timely and lowcost manner. By streamlining the process, the adoption of single-use technologies can progress more efficiently and rapidly, with a higher sense of process consistency and product quality, at lower cost. The BPSA has already helped the industry significantly by educating and providing best-practice guides for the adoption of singleuse technologies. BPSA documents such as extractables/leachables guides, white papers on component quality test methods, irradiation/sterilization, disposal, and the economic advantages of singleuse are good examples of what the BPSA has been able to accomplish in a relatively short period of time.

The BPSA QAT will be a consensus document that identifies commonalities of various templates existing today and will be more effective as a starting point for negotiations. Application of the BPSA QAT will be voluntary (as a trade association, BPSA has no mandate authority).

PROGRESS TO DATE

At the moment, the BPSA QATTF is comparing existing templates and will be creating subsections to the document that cover the key points that the QAT must have. Some of the issues to be addressed will be identification of critical changes, change control and notification, subcomponent supplier qualification, component origin information, customer involvement in changes to standard products, levels of disclosure, and custom-product quality specifications. Rather than hinder uptake, we envision the BPSA QAT will provide higher assurance of quality supply and facilitate faster uptake of singleuse equipment by reducing the time, cost, and effort to establish agreements.

The BPSA QATTF has been working to define a process for developing the document, which is expected to be completed over the next 4–6?months. This template will be another tool that biopharmaceutical companies and suppliers can use to ensure that high quality, safe drug and vaccine products can be delivered to patients at the time they are needed, to save and improve the quality of peoples' lives. Interested parties are invited to contact the BPSA for corporate membership and participation information.

Based on preliminary feedback from singleuse suppliers and users, we anticipate that, when published, the impact of the BPSA QAT will be positive. Smaller companies are more likely to accept it as offered while larger companies are likely to demand customization, but the consensus is that the BPSA QAT will facilitate the finalization of agreements in a more expedient manner. Requests for quality agreements are likely to increase as regulatory agencies come to expect these to be in place between users and suppliers of singleuse process equipment.

ACKNOWLEDGMENTS

With thanks to Todd Kapp of Renolit, Jamie Ethier of Millipore, Ann Rich of ThermoFisher, and Terry Cusick of Pall for their valuable input.

For further information about BPSA's publications and activities, please visit http://www.bpsalliance.org/.

JEROLD MARTIN is senior vice-president for Global Scientific Affairs, Biopharmaceuticals, at Pall Life Sciences and chairman of the board for Bio-Process Systems Alliance (BPSA),
.

REFERENCE

1. pharmtech.findpharma.compharmtech/survey/surveyList.jsp?id=683202, accessed Aug. 2011.


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

Compounding Pharmacy Issues Recall, But Challenges FDA Decision
July 22, 2014
AbbVie's Acquisition of Shire Could Save $8 Billion in Taxes
July 21, 2014
AstraZeneca Reveals Design for New Global R&D Center and Corporate Headquarters
July 18, 2014
AbbVie to Acquire Shire for $54.7 Billion
July 18, 2014
Particulate Matter Prompts Baxter's Recall of IV Solutions
July 17, 2014
Author Guidelines
Source: BioPharm International Supplements,
Click here